|
JOBS | TENDERS | DATING |
|
|
THE SMART NEWS SOURCE | Feb 11 2012 00:49 | LAST UPDATED Feb 11 2012 00:49 |
|
South African generic drugs group Cipla Medpro posted a 26,8% rise in full-year profit helped by its relationship and product pipeline from its Indian partner. Cipla Medpro, which rebuffed rival Adcock Ingram's R2,1-billion takeover bid last year, said on Thursday headline earnings per share rose to 36,6 cents compared with 29,1 cents in the previous year. The company, whose small manufacturing unit suffered losses of R35,6-million, enjoys a relationship with Indian drug maker Cipla Limited, which delivers a regular flow of first-to-market patent-expired molecules. Cipla Medpro said it would add 20 new drugs this financial year, targeting a host of cancers including breast, colon and lung cancer -- three of the leading causes of cancer related deaths globally. Revenue rose 26,9% to R1,26-billion, while gross profit margin fell to 49,2% from 49,6%. -- Reuters  CONTINUES BELOW TOPICS IN THIS ARTICLE
comment guidelines
|
IN THIS WEEK'S PAPER
SUBSCRIBE: - Paper edition - iPad edition (NEW!) - Kindle edition - Digital edition Read stories online  @mailandguardian - Top stories & newsflashes @NicDawes - M&G editor Nic Dawes @ChrisRoperZA - Editor, M&G Online @amabhungane - M&G Centre for Investigative Journ @mgfeed - Our whole news feed Advertisements |
Contact Us | About Us | Story Tip-offs | Social media policy | Online Advertising | Print Advertising | Subscriptions | Topics A-Z | Mobile Sites | Privacy Policy | RSS Feed
All material © Mail & Guardian Online. Material may not be published or reproduced in any form without prior written permission.
 |
 |